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Abstract
Background: The development and course of Crohn’s disease (CD) is related to both genetic and environmental factors.
Smoking has been found to exacerbate the course of CD by increasing the risk of developing fistulas and strictures as well
as the need for surgery, possibly because of an interaction between smoking or nicotine on macrophage function and the
intestinal microvasculature. Several genes are involved in the pathogenesis of CD, and in this study the gene expression
differences of the descending colonic mucosa were investigated in CD (smokers or never smokers) and controls (smokers or
never smokers).
Aim: To identify any difference in gene expression of the descending colonic mucosa between smoking and never-smoking
CD patients (and controls) by determining genetic expression profiles from microarray analysis.
Methods: Fifty-seven specimens were obtained by routine colonoscopy from the included material: CD smokers (n=28) or
never-smokers (n=14) as compared to fifteen healthy controls (8 smokers and 7 never-smokers). RNA was isolated and gene
expression assessed with Affymetrix GeneChip Human Genome U133 Plus 2.0. Data were analyzed by principal component
analysis (PCA), Wilcoxon rank sum test and multiple linear regressions. Real-time (RT) PCR was subsequently applied to verify
microarray results.
Results: The PCA analysis showed no intrinsic clustering of smokers versus never-smokers. However, when Wilcoxon rank
sum test corrected with Q values were performed, six known genes were significantly expressed differently in the inflamed
CD smokers as compared to the inflamed CD never-smokers: ring finger protein 138 (RNF138), metalothionein 2A (MT2A)
and six transmembrane epithelial antigen of the prostate 3 (STEAP3), SA hypertension-associated homolog, PGM2L1 and
KCNJ2. The subsequent RT-PCR-analyses verified, however, that only RNF138, MT2A and STEAP3 were significantly up-
regulated in CD smokers in specimens with inflammatory activity of the descending colon.
Conclusions: The present study demonstrates that the genes, RNF138, MT2A, and STEAP3 are differently expressed in the
inflamed descending colon of smoking versus never-smoking CD patients, which might be of relevance for the poorer
clinical course among CD smokers. Many gastroenterologists are still not totally aware of the benefits of smoking cessation
in relation to CD, and do not put much effort into getting the patients to quit, therefore more information on the negative
effects of smoking, seems warranted.
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Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel disease
(IBD) which might affect any part of the gastrointestinal tract,
causing a wide range of complications including ulceration,
fibrostenosis, and fistula development resulting in symptoms like
abdominal pain, fever, diarrhea and weight loss during episodes
with flare-ups.
Development of the disease is believed to be related to both
genetic heritage and various environmental factors [1], such as
smoking. While smoking represses activity of ulcerative colitis (UC)
[2] it has, however, been shown to exacerbate the course of CD
[3,4], why it is intuitively believed that smoking has different
effects on the ileum and colon, though the results of larger studies
on this matter have been inconsistent [5,6]. Furthermore, smoking
worsens the course of CD by increasing the risk of developing
fistulas and strictures as well as accelerating the need for surgery,
probably due to an increased influx of neutrophils into the
intestinal mucosa [7,8]. These detrimental effects of smoking in
CD could additionally be related to the nicotine-induced
suppression of antimicrobial activity and immune responses by
macrophages [9], which might further compound any deficiency
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6210in the host response to luminal bacteria. Other components of
tobacco smoke, such as oxidizing chemicals, could also be of
importance; these unlike nicotine, have prothrombotic effects that
may exacerbate microvasculature abnormalities and ischemia
[10,11]. In this way, an individual at risk of CD who smokes might
increase the chance of developing the disease, because of the
effects of smoking or nicotine on macrophage function and/or the
intestinal microvasculature.
DNA microarray technology allows a wide survey of gene
expression. It is based on standard hybridization techniques,
through scaling up, which allows simultaneous hybridization of
thousands of genes fixed on a single solid matrix with mRNA from
a single tissue sample [12]. DNA microarrays rely on known
nucleotide sequences fixed on a matrix that bind complementary
to unknown nucleotide sequences expressed on sample tissues.
Since it is believed that there are many genes involved in the
pathogenesis of CD, the hypothesized association between the
clinical phenotype and the gene expression found in the colonic
mucosa of CD patients is likely to be represented by a
combinatorial expression pattern of different genes.
In this study, we aimed to identify any gene expression
differences between the descending colonic mucosa of smoking
and never-smoking CD patients, by determining genetic expres-
sion profiles from DNA microarray analysis.
Methods
Patients and controls
The present study included 65 humans: 48 CD patients and 17
control subjects (i.e. patients who underwent investigations including
colonoscopy, but where all tests were normal). Six CD patients and
two control subjects were excluded, as their smoking status could not
be established unambiguously. Thus, fifty-seven persons hereof 42
CD patients and 15 control subjects participated in this study
(Table 1). A further division of patient groups was based on smoking
or never-smoking status. Data from control subjects were used to
obtain the normalization of absolute values of mRNA expression.
Ongoing treatment of the CD patients was obtained from a
questionnaire of the patients themselves and confirmed in medical
records, as shown in Table 1. We scored the disease activity by use
of Crohn’s disease Activity Index (CDAI) [13].
The diagnosis of CD was established on internationally accepted
criteria [14], where exclusion criteria excluded people aged over 75
years or below 18 years, where there was clinical evidence of active
infections, who had recently used (within 2 weeks) antibiotics, and
those who were pregnant or had severe mental illness.
The project was approved by the Scientific Ethics Committee of
the Copenhagen Region and was performed in accordance with
the Helsinki V Declaration. Informed consent was obtained both
written and verbally from all participating patients.
Tissue Samples
All samples were obtained endoscopically from the descending
colon. This part of the intestinal tract was chosen in order to focus
on the colonic involvement concerning CD and smoking, to make
future comparisons with specimens from patients with ulcerative
colitis possible, and to avoid any intersegmental variation in gene
expression.
Biopsies for RNA extraction were immediately stabilized in
RNA-later (Ambion, Austin, TX, USA). Each tube contained two
specimens, which were sampled from the same area, with no more
than 2 cm distance in between them. These two specimens were
pooled for extraction of RNA. Histopathological evaluation was
conducted on biopsies sampled from adjacent areas. This
evaluation was performed in an unblinded fashion by staff
pathologists, in accordance with well-established criteria and
focused on confirming the degree of inflammation [15]. Only
biopsies showing both macroscopic and histological signs of
inflammation, were considered inflamed. Further, in the non-
inflamed patients included into this study, investigations by MRI,
x-ray and/or ultrasound did not reveal inflammation in other
segments of the gastro-intestinal tract.
Sample preparation, hybridization, detection and
quantification of signals
Intestinal specimens were put immediately in RNA-later at 4uC,
where they were kept for 48 h in order to minimize RNA
Table 1. Clinical details.
CD inflamed CD non-inflamed Controls
Smokers Never smokers Smokers Never smokers Smokers Never smokers
n=12 n=6 n=16 n=8 n=8 n=7
Age (years)(mean, range) 34 (18–53) 35 (19–60) 37 (23–58) 32 (20–57) 41 (18–74) 30 (18–51)
Sex (M/F) 6/6 3/3 5/11 4/4 2/6 1/6
CDAI (153,) (163,)( .148) (.143) - -
Years with disease (mean, range) 7 (0–20) 1 (0–3) 13 (2–30) 10 (1–30) - -
Medication:
Mesalazine 2 1 2 4 - -
Azathioprine 1 0 4 1 - -
Budesonide 0 0 1 1 - -
Systemic glucocorticoids 1 3 1 1 - -
Infliximab 2 0 1 0 - -
None 4 3 5 1 - -
Methotrexate 2 0 2 0 - -
CD: Crohn’s disease, CDAI: Crohn’s Disease Activity Index.
doi:10.1371/journal.pone.0006210.t001
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RNA isolation was initiated. RNA was extracted with Trizol
(Invitrogen, Carlsbad, CA, USA) chloroform and precipitated with
isopropanol [16]. Further purification was obtained with the
RNeasy mini kit (Qiagen, Valencia, CA, USA). Integrity and purity
were verified with an Agilent Bioanalyzer (Palo Alto, CA, USA). In
accordance with the Affymetrix protocol (Affymetrix, Santa Clara,
CA, USA), double-stranded cDNA was synthesized from total
RNA, and an in vitro transcription reaction was subsequently
performed to produce biotin-labeled cRNA from the cDNA [17].
The cRNA was fragmented and a hybridization mix was prepared,
which included the fragmented target, probe array controls, bovine
serum albumin (BSA), and herring sperm DNA [17]. In this
experiment, the Affymetrix GeneChip Human Genome U133 Plus
2.0 was applied, which contains more than 54.000 probe sets
representing approximately 38.500 genes and gene sequences. The
hybridized probe array was subsequently stained with fluorescent
protein streptavidin-phycoerythrin (SAPE) [18] and scanned with a
GeneArray scanner at the excitation wavelength of 488 nm. The
amount of light emitted at 570 nm is proportional to the bound
target at each location on the probe array.
All significant transcript levels were measured by real-rime
reverse transcription (RT)-PCR using the LigthtCycler system
(Roche, Manheim, Germany) according to the principles previ-
ously described in details [19]. Primers were selected using the
Primer Bank resource [20]. Normalization was performed using
the transcript level of ribosomal protein L10 (RPL10; Primer Bank
ID 5174431a1) as reference.
Data analysis
As i n g l el o g 2e x p r e s s i o nm e a s u r ef o re a c hp r o b es e tw a sc a l c u l a t e d
from image files (.CEL format) using the robust multi-array analysis
(RMA) procedure [21] with quantile normalization implemented in
the Affymetrix library for the R statistical environment [22]. Probe
sets with background level signal intensities were removed by filtering
out probe sets where the lower quantile was below five. 14.378 probe
sets remained after filtering. These calculations were performed on
the total set of 57 observations and a subset of these observations has
previously been analyzed to search for correlations between the
colonic gene expression profile and clinical symptoms [17]. The
normalized and filtered data were subsequently analyzed by the
unsupervised multivariate analysis tool principal component analysis
(PCA) using Simca P11 (Umetrics, Umea ˚, Sweden). PCA was used as
it reduces data complexity in a rational way without any prior
knowledge of categories so as to determine if any intrinsic clustering
or outliersexisted withinthe data set. Five different modelswere built:
Inflamed samples, non-inflamed samples, control samples, CD
samples, and all samples. The number of components in the PCA
models was determined by using the autofitting option in Simca P11.
In addition, Wilcoxon rank sum test was performed comparing
smokers versus never-smokers in each of four different groups:
Controls,CD non-inflamed, CD inflamed, and all observations taken
together. All significant results were corrected by calculating the Q
value. Wilcoxon rank sum test was also used when comparing real-
timeRT-PCR resultsfromCDinflamed smokersand never-smokers,
and regression analyses were used to test for confounding factors as
age, gender, and years with disease. However, because of the number
of patients included it would not be sound to use all 4 variables in one
model. Instead all variables were tested univariately, and only
significant values were tested in a multiple regression model.
The RMA processed data and the image files have been
deposited in public databases: ArrayExpress database (CD
patients, accession number E-TABM-118) and Gene Expression
Omnibus (controls, accession number GSE11831), and the
reported microarray data were handled in accordance with the
MIAME guidelines.
Results
Twenty-eight of the CD diagnosed patients and eight of the
controls entered the smoking group (Table 1). Using PCA the
smokers versus never-smokers relationship was analyzed. Five different
models were constructed by dividing the observations into different
sets: Inflamed, non-inflamed, controls, CD and all samples. For each
component, score plots were performed and observations colored
according to smoking status (see Fig. 1). With no component did an
asymmetric distribution of observations of different smoking status
become obvious in the score plotsof any of the PCA models, nor were
any outliers detected. Hence, no correlation between the smoking
status and gene expression levels seems to exist, which indicates the
absence of a specific ‘‘smoking’’ gene expression pattern. However, a
tendency of an asymmetric distribution was observed with CD
inflamed smokers versus CDinflamednever-smokers(seeFig.1),anda
possible univariate correlation was suspected.
In order to search for such a univariate relationship between the
expression level of a single or a few genes and smoking status, a
Wilcoxon rank sum test was performed for each gene according to
the smoking status. This was carried out in the subgroups for CD
inflamed, CD non-inflamed and healthy control samples (data not
shown). Twelve known genes were found to be differentially
regulated in the CD inflamed smokers group versus the CD
inflamed never-smokers group (Table 2). However, only six genes
had fold changes higher than 1.5, which was chosen as the
minimal fold change relevant to report. The expression of these six
genes and their potential association with gender and age were
tested (linear regression analysis) without any significant correla-
tions. Regarding years with diagnosis the patients were divided in two
groups: above and below 10 years. It was noted that the 4 patients
with diagnosis above 10 years were all smokers, but the association
(Fischer’s exact test) was not significant (p=0.2). Two of the six
genes were found to be differentially expressed (linear regression)
in patients with symptoms for more than 10 years: STEAP family
member 3 (STEAP3) and phosphoglucomutase 2-like 1
(PGM2L1). In a multiple regression analysis for STEAP3, the p-
values were ,0.0001 for smoking status, and 0.1 for diagnosis
above 10 years, whereas for PGM2L1 the p-values were 0.0004 for
smoking status and 0.02 for diagnosis above 10 years.
In order to verify the DNA micro-array findings, the expression
measures of ring finger protein 138 (RNF138), PGM2L1,
metallothionein 2A (MT2A), STEAP3, and potassium inwardly-
rectifying channel, subfamily J, member 2 (KCNJ2) were
quantified by RT-PCR in all included samples from the CD
inflamed group. The probe set 210377_at originally annotated as
probing the gene SA hypertension-associated homolog in fact probe
several genes on chromosome 16 and was therefore omitted for
further analysis. Using the Wilcoxon rank sum test this resulted in
a significant higher number of RNF138 (two-sided exact test:
p=0.02), MT2A (two-sided exact test: p=0.03), and STEAP3
(two-sided exact test: p=0.002) copies in the colonic mucosal
biopsies from CD smokers as compared to CD never-smokers,
hence verifying the DNA micro-array results (Fig. 2). However,
PGM2L1 and KCNJ2 did not reach a statistical significance
although the trends in their expression levels were the same in
both the RT-PCR and the micro-array analysis.
Discussion
Smoking is an important environmental factor in IBD, with
diametrically opposite effects in UC and CD [23]. Never smoking
Smoking and Gene Expression
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6210Figure 1. PCA score plot of gene expression from inflamed samples. Gene expression data generated by the Affymetrix HGU U133 Plus 2.0
GeneChips platform and derived from 18 CD patients all with inflamed mucosa were analyzed by PCA. A three-component model was developed
explaining a total of 54% (R
2X) of the variation in the data set and a predictability of 0.22 (Q
2). The figure shows a score plot with the first two
dimensions. Observations are coded according to smoking status. There is no obvious separation of the samples. Analogous PCA models were made
for four other datasets (non-inflamed, control, CD and all samples) without any intrinsic clustering.
doi:10.1371/journal.pone.0006210.g001
Table 2. Differential expressed genes on DNA micro-arrays in CD inflamed smokers vs. CD inflamed non-smokers.
ProbeID Gene Title
Gene
Symbol
Wilcoxon
rank sum Q value
Fold
changes
212185_x_at metallothionein 2A MT2A 0,000108 0,109611 +3
206765_at potassium inwardly-rectifying channel, subfamily J, member 2 KCNJ2 0,000108 0,109611 +2,4
218424_s_at STEAP family member 3 STEAP3 0,000108 0,109611 +2,1
229553_at phosphoglucomutase 2-like 1 PGM2L1 0,000108 0,109611 21,6
210377_at SA hypertension-associated homolog (rat) SAH 0,000108 0,109611 +1,6
218738_s_at ring finger protein 138 RNF138 0,000108 0,109611 +1,5
225602_at chromosome 9 open reading frame 19 C9orf19 0,000108 0,109611 +1,4
232165_at epiplakin 1 EPPK1 0,000108 0,109611 +1,4
223272_s_at chromosome 1 open reading frame 57 C1orf57 0,000108 0,109611 +1,2
227388_at tumor suppressor candidate 1 TUSC1 0,000108 0,109611 +1,2
213145_at F-box and leucine-rich repeat protein 14 FBXL14 0,000108 0,109611 +1
203012_x_at ribosomal protein L23a RPL23A 0,000108 0,109611 +0,4
The significance level for the Wilcoxon’s rank sum was set at 2610
24.
The Q value is the minimum false discovery rate set at 0.15.
Fold Change: up-regulated (+), down-regulated (2) in the smokers.
doi:10.1371/journal.pone.0006210.t002
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UC [24], whereas smoking increases the risk of developing CD in
the general population [24]. In patients with CD, smoking is
extremely harmful, and smoking cessation is followed by
improvement of the disease [24,25]. The reason for the opposite
association with smoking status is still unclear.
When nicotine has been administered to patients with CD as an
enema, some gained benefit, but none deteriorated [23]. Of
possible relevance to this observation is the finding that smoking is
associated with a higher risk of ileal disease and less colonic
involvement [6], and it is believed that smoking has different
effects on the ileum and colon [3]. Thus, a larger study of 1,947
IBD patients from 19 European centers of which 630 had CD
indicated, that CD patients who smoked were less likely to have
colonic involvement (p,0.001), suggesting that smoking might
protect the colon from inflammation [6]. Bridger et al [26] defined
339 sibling pairs with IBD, and of those, 89 were discordant for
smoking. The sample included 23 pairs who were also discordant
for IBD type, and in 21 of these pairs, the smoker developed CD,
and the never-smoker UC (OR 10.5 95% CI 2.6–92, p,0.0001).
This study additionally suggested that smoking status increase the
risk of ileal involvement of CD. However, another study of a
French cohort of 978 UC and 688 CD patients, showed that the
negative effect of smoking also applied to CD colitis [5].
The etiology of smoking on the course of CD is still unclear, and
potentially important mechanisms include cell cycling and
apoptosis, immune modulation, permeability and mucous com-
position, gut vascularity, and perturbation in arachidonate
metabolite production [27,28]. Of the more specified mechanisms
by which smoking modulates the immune system is the action of
nicotine or the nicotinic acetylcholine receptor a7 subunit [29].
This receptor is expressed on macrophages and mediates the
reduction in lipopolysaccharide stimulated TNF-a production,
induced by nicotine and vagal nerve stimulation [30]. CD is
further characterized by a decreased total radical-trapping
antioxidant potential [31], and abnormalities of the microvascu-
lature [32]. Smoking, through increased carbon monoxide
concentration, may amplify the impairment in vasodilatation
capacity of the chronically inflamed microvessels, resulting in
ischemia, and perpetuation of ulceration and fibrosis [10]. The
three significantly upregulated and PCR-verified genes identified
in the present paper add further explanatory components to the
proposed etiology of smoking on the course of CD.
The first significantly up-regulated gene, RNF138, was in the
CD inflamed smokers compared to the CD inflamed never-
smokers with a fold change of 1.5. RNF138, initially named
NARF (NLK-associated RING finger protein) [33], has been
shown to ubiquitinate TCF (T-cell factor)/LEF (lymphoid
enhancer factor) proteins, which leads to their degradation and
hence inhibits Wnt signalling [34]. Wnts are secreted cysteine-rich
glycoproteins that act as short-range ligands to locally activate
receptor-mediated signalling pathways, and they have been shown
Figure 2. Box plot of RT-PCR results. Real time RT-PCR quantification of genes differentially expressed in inflamed CD smokers and non-smokers.
Transcript copy numbers for ring finger protein 138 (RFP138), phosphoglucomutase 2-like 1 (PGM2L1), metallothionein 2A (MT2A), STEAP family
member 3 (STEAP3), and potassium inwardly-rectifying channel, subfamily J, member 2 (KCNJ2) were measured in RNA extracted from all inflamed
CD biopsy samples. The copy numbers of ribosomal protein L10 were used for normalization between samples. The box border represents the
interquartile range, and the horizontal line in the box is the median. *, significant difference between smokers and non-smokers.
doi:10.1371/journal.pone.0006210.g002
Smoking and Gene Expression
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differentiation of the mucosa of the small intestine and colon [35].
The best understood Wnt signalling pathway is the Wnt/b-catenin
pathway, which ultimately results in an activation of the DNA
bound TCF/LEF transcription factors. Kuhnert et al. [35]
injected an adenovirus expressing Dick-kopf-1 (Dkk1), a soluble
Wnt antagonist, into adult mice and were able to demonstrate an
extensive Dkk1 repression of the TCF/LEF target genes and
ablated epithelial proliferation in small intestine and colon
accompanied with progressive architectural degeneration with
loss of crypts, villi, and glandular structure to the extent of mucosal
ulceration and lethality. This conforms with the described role of
the Wnt/b-catenin pathway as a ‘‘master switch that controls
proliferation versus differentiation’’ [36], and an obvious reason
why a wide variety of different abnormalities in this pathway have
been found to play pivotal roles in oncogenesis, including
colorectal cancers [37,38]. Consequently, the up-regulated
RNF138 in the CD inflamed smokers might be one of the factors
why smokers with CD have a poorer clinical prognosis than never-
smokers with CD, as their colonic mucosal regenerative capabil-
ities are impaired due to the inhibitory effect of RNF138 on the
Wnt/b-catenin pathway.
The second upregulated gene by a factor 2.1 was STEAP3 (also
named TSAP6 or dudlin-2) which plays a crucial role in
tumorogenesis by controlling cell-cycle progression and apoptosis
[39], and it might additionally have a pivotal role in regulating
vesicular trafficking and secretion [40]. Thus steap proteins appear
to play an important role in neoplasia [41]. In addition, STEAP
proteins were recently shown to function as metalloreductases.
STEAP3 is widely expressed in the body and overexpression
stimulates the reduction of iron [42].
The third gene, which was upregulated by a factor 3.0, was
MT2A and is involved in induction of apoptosis [43,44], an
important feature in IBD not only for the inflammation but also
for malignant transformation [45]. Further, the MT2A protein
possess a protection against oxidation injury in particular in
inflammatory conditions [46], which might be of importance for
the clinical course of CD. Metallothioneins moreover comprise a
family of cysteine-rich low molecular weight proteins that form
complexes with heavy metal ions such as zinc and copper, but also
xenobiotic heavy metals such as mercury, silver and cadmium.
Recent data have shown that placental MT2 isoform is
upregulated in response to smoking [47]. Cigarette smoke contains
about 30 different metal ions including cadmium, zinc, arsene,
copper, aluminium, antimony, lead, nickel, chromium and iron
[48]. Many metals are reactive and promote oxidative stress and
leading to toxic effects and carcinogenesis [48].
Taken together, the upregulation of STEAP3 and MT2 isoform
may result from an increased load of metal ions including ferric
ions. Apart from local hypersensitivity reactions it is unknown if
metalions promote inflammation, but our results indicate that
metal ions might play a role in CD.
Two other genes showed significantly altered expression levels
on micro-arrays from CD inflamed smokers as compared to the
CD inflamed never-smokers: PGM2L1 was 1.6 fold down-
regulated, whereas KCNJ2 was upregulated by a factor 2.4.
However, a subsequent RT-PCR verification of these genes did
not reach a statistical level even though there was a trend towards
that PGM2L1 was lower, and KCNJ2 and higher, respectively in
mucosal biopsies from CD smokers compared to CD never-
smokers.
A range of genes (e.g. CARD15, IBD5 and IL23R) well known
to be associated with CD did not show up in this study as these
genes are not predominant in the group of CD patients, and
because this genome-wide gene association study focused on the
smoking phenotype. The lack of a ‘‘smoking’’ gene expression
pattern as found in the present paper suggests that no gene
expression profile can be attributed to the colonic area of smokers.
However, it might be concluded that the genes: RNF138,
STEAP3 and MT2A are differently expressed in inflamed
descending colonic mucosa of CD smokers versus never-smoking
CD patients, supporting the notion that the colonic mucosa from
that segment of CD patients is in fact affected by the patient’s
smoking status – a circumstance, which has to be taken into
consideration when performing genome-wide gene expression
profiles of CD patients and probably also of UC patients. Further,
five of CD smokers and one CD never-smoker did receive
azathioprine treatment. However, an earlier study of Csillag et al.
did not reveal any effect of azathioprine per se on colonic gene
expression [49]. It should be noticed, that an even more
pronounced difference might be revealed if ileal specimens
obtained by ileoscopy were investigated instead of colonic biopsies.
The identification of three genes upregulated in CD smokers,
which have a more severe clinical course than non-smokers, might
add an important piece in the complex puzzle of the inflammatory
process in CD. The question of how smoking alters the expression
remains unanswered and needs attention together with functional
analyses of the identified genes in future studies. Many
gastroenterologists are still not aware of the benefits of smoking
cessation in relation to CD, and do not put efforts into getting the
patients to quit, therefore more information on the negative effects
of smoking, are warranted.
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